Show simple item record

dc.contributor.authorBlank, C
dc.contributor.authorLorigan, Paul C
dc.contributor.authorSchachter, J
dc.contributor.authorRobert, C
dc.contributor.authorRibas, A
dc.contributor.authorLong, G
dc.contributor.authorArance, A
dc.contributor.authorMortier, L
dc.contributor.authorDaud, A
dc.contributor.authorCarlino, M
dc.contributor.authorMcNeil, C
dc.contributor.authorLotem, M
dc.contributor.authorLarkin, J
dc.contributor.authorNeyns, B
dc.contributor.authorPetrella, T
dc.contributor.authorHamid, O
dc.contributor.authorZhou, H
dc.contributor.authorEbbinghaus, S
dc.contributor.authorIbrahim, N
dc.contributor.authorGrob, J
dc.date.accessioned2016-12-16T16:10:54Z
dc.date.available2016-12-16T16:10:54Z
dc.date.issued2016
dc.identifier.citationPembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006. 2016, 26: E117-E118 Melanoma Resen
dc.identifier.urihttp://hdl.handle.net/10541/620061
dc.language.isoenen
dc.titlePembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006.en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentNetherlands Cancer Institute, Amsterdam, Netherlandsen
dc.identifier.journalMelanoma Researchen


This item appears in the following Collection(s)

Show simple item record